Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Lundbeck to Cut 600 Sales Jobs in Europe on Drug Lineup

H. Lundbeck A/S, the Nordic region’s second-largest drugmaker, said it’s eliminating 600 sales jobs in Europe as it prepares new products that will lead to a change in its lineup.

Reorganization costs may total as much as 500 million kroner ($85 million) this year, the Copenhagen-based company said in a statement today. The job cuts will affect sales personnel who work with general practitioners, said Mads Kronborg, a spokesman.

Lundbeck expects European approval of its alcoholism treatment nalmefene by the end of 2012. It’s also planning to submit a new antidepressant, known as LU AA21004, for regulatory clearance in the U.S. and Europe later this year.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.